Servier is launching, in partnership with the International Society of Hypertension (ISH), a new edition of "Because I Say So", a global public awareness campaign on the importance of taking your antihypertensive treatment every day and following the advice from his doctor.Launched in more than 40 countries, "Because I Say So," is a global awareness campaign aimed at patients being treated for hypertension to encourage them to follow their doctor's advice, not to stop their treatment prematurely and to take it every day.David Pédelabat-Lartigau, Hypertension Marketing Director at Servier, says: "Servier has been committed to the fight against hypertension for 50 years and we know that there is still a lot to be done to improve blood pressure control, since more and more more people suffer from hypertension and its effects.This new campaign, carried out in collaboration with the International Hypertension Society, aims to raise awareness of the serious consequences of non-adherence to antihypertensive treatment, known to be one of the reasons for the low rate of blood pressure control in the population. hypertensive.»Launched in 2018, the first BecauseIsayso campaign was intended to raise awareness among the general public about the importance of measuring blood pressure and encourage a growing number of people to have their blood pressure checked.In the second edition in 2019, the campaign reached more than 150 million people in 70 countries.With this new section devoted to compliance, the importance of awareness campaigns to arouse the general public's interest in health issues.A first part of this membership campaign was deployed during the Covid-19 pandemic.The BecauseIsayso concept has been adapted to the health crisis and 43.5 million people have received the publications and messages broadcast worldwide on various social networks (Facebook, LinkedIn and Twitter).For more information: www.becauseisayso.netShare the post "Hypertension: Servier launches a new edition of its consumer campaign “Because I Say So”"Sanofi and Innovent Biologics announced a collaboration to bring innovative medicines to patients with hard-to-treat cancers in China.Innovent is a cutting-edge biopharmaceutical company with strong clinical development capabilities and a large commercial footprint in China.Kite, a Gilead group company, has announced that the Haute Autorité de Santé (HAS) has granted early access authorization to its CAR T cell therapy Yescarta® (axicabtagene ciloleucel) for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). ) refractory or relapsed within 12 months after the end of first-line treatment and eligible for salvage chemotherapy followed by intensification chemotherapy for autologous hematopoietic stem cell transplantation.Ipsen announced today that the Phase III RESILIENT study did not meet its primary endpoint of overall survival (OS) compared to Topotecan.The study is evaluating Onivyde® (liposomal irinotecan injection) versus topotecan in patients with small cell lung cancer (SCLC) who progressed on or after first-line platinum therapy.TME Pharma, a biotechnology company specializing in the development of novel therapies for the treatment of cancer by targeting the tumor microenvironment (MET), announced that the first patient in the expansion arm of the Phase 1/2 clinical trial, GLORIA, evaluating the combination of NOX-A12, radiation therapy and the PD-1 immune checkpoint inhibitor pembrolizumab, was enrolled and received its first week of treatment.Valneva, a company specializing in vaccines, confirmed on Monday August 1 the amendment to its advance purchase agreement with the European Commission, as announced by the company on July 20, 2022, the period during which member states could exercise their right to expired withdrawal.Celyad Oncology, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor-carrying T-cell (CAR-T) treatments for cancer, has just announced that the US Food and Drug Administration (FDA) lifted the clinical hold for Phase 1b trials of CYAD-101-002 (KEYNOTE-B79) after the Company made changes to the eligibility criteria for the trial.Cellectis, a clinical-stage biotechnology company that uses its pioneering TALEN® genome-editing technology to develop potential innovative therapies for the treatment of serious diseases, announced that it has obtained approval from the Food and Drug Administration (FDA) to start a Phase 1/2a clinical trial for its product candidate UCART20x22 in relapsed or refractory non-Hodgkin's lymphoma (NHL).Every Monday, our free newsletter